RxDoctor Payments Data

Gayathri Raman, MD

Family Medicine · Chesterfield, MONPI 1568461176

Payments from drug & device makers

$458in general payments, 2019–2025

Across 23 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$170
  • Tosoh Bioscience, Inc.$112
  • Abbott$77
  • Novo Nordisk$29
  • Novartis$27
  • Lilly USA, LLC$16
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$34676%
  • Gifts$11224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)11$170
Tosoh Bioscience, Inc.1$112
Abbott4$77
Novo Nordisk2$29
Novartis2$27
Lilly USA, LLC1$16
AbbVie1$14
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$458 in reported general payments places this provider in the 50th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$27,503
Medicare patients
64
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide73$90,478
EliquisApixaban12$19,229
OzempicSemaglutide14$15,246
Liothyronine Sodium78$4,903
ConcertaMethylphenidate Hcl11$4,481
VyvanseLisdexamfetamine Dimesylate11$4,156
SynthroidLevothyroxine Sodium32$4,145
Levothyroxine Sodium112$1,366
Albuterol Sulfate HfaAlbuterol Sulfate25$1,189
Methylprednisolone119$803
Gabapentin25$765
Pregabalin12$630
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)23$547
Alprazolam45$534
Omeprazole38$523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$16$90,47873 claims
Novo NordiskOzempic$29$15,24614 claims
AbbVieSynthroid$14$4,14532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →